ARCT RSI Chart
Last 7 days
2.2%
Last 30 days
-19.2%
Last 90 days
-16.3%
Trailing 12 Months
2.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 281.0M | 264.5M | 296.2M | 166.8M |
2022 | 15.5M | 40.6M | 51.5M | 206.0M |
2021 | 9.0M | 8.7M | 8.8M | 12.4M |
2020 | 19.1M | 11.3M | 10.3M | 9.5M |
2019 | 17.0M | 18.3M | 19.5M | 20.8M |
2018 | 0 | 0 | 0 | 15.8M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 25, 2024 | chivukula pad | sold | -610,574 | 35.02 | -17,435 | chief scientific officer & coo |
Mar 19, 2024 | chivukula pad | sold | -299,839 | 35.0075 | -8,565 | chief scientific officer & coo |
Nov 01, 2023 | chivukula pad | sold | -93,601 | 18.7203 | -5,000 | chief scientific officer & coo |
Oct 02, 2023 | chivukula pad | sold | -128,062 | 25.6123 | -5,000 | chief scientific officer & coo |
Sep 01, 2023 | chivukula pad | sold | -157,264 | 31.4527 | -5,000 | chief scientific officer & coo |
Aug 15, 2023 | sassine andy | acquired | 21,248 | 17.374 | 1,223 | chief financial officer |
Aug 01, 2023 | chivukula pad | sold | -174,550 | 34.91 | -5,000 | chief scientific officer & coo |
Jul 14, 2023 | kummerfeld keith c | sold | -243,880 | 35.00 | -6,968 | see remarks |
Jul 14, 2023 | kummerfeld keith c | acquired | 62,408 | 8.95642 | 6,968 | see remarks |
Jul 14, 2023 | chivukula pad | sold | -875,250 | 35.01 | -25,000 | chief scientific officer & coo |
Which funds bought or sold ARCT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Zurcher Kantonalbank (Zurich Cantonalbank) | added | 5.13 | 30,352 | 271,241 | -% |
Apr 25, 2024 | Allworth Financial LP | unchanged | - | 336 | 5,066 | -% |
Apr 25, 2024 | Lindbrook Capital, LLC | unchanged | - | 152 | 2,296 | -% |
Apr 25, 2024 | TRITONPOINT WEALTH, LLC | unchanged | - | - | 885,117 | 0.09% |
Apr 25, 2024 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | unchanged | - | 5,000 | 70,000 | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -13.03 | -287,022 | 3,903,910 | -% |
Apr 24, 2024 | DekaBank Deutsche Girozentrale | unchanged | - | 9,000 | 1,410,000 | -% |
Apr 24, 2024 | Robeco Institutional Asset Management B.V. | unchanged | - | 26,755 | 403,349 | -% |
Apr 24, 2024 | Assenagon Asset Management S.A. | new | - | 1,865,350 | 1,865,350 | -% |
Apr 23, 2024 | AMALGAMATED BANK | reduced | -62.67 | -41,000 | 27,000 | -% |
Unveiling Arcturus Therapeutics Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Arcturus Therapeutics Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Arcturus Therapeutics Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -31.6% | 30,855,000 | 45,140,000 | 10,519,000 | 80,285,000 | 160,293,000 | 13,369,000 | 27,093,000 | 5,244,000 | 5,794,000 | 2,437,000 | 2,001,000 | 2,127,000 | 2,238,000 | 2,333,000 | 2,322,000 | 2,646,000 | 2,968,000 | 3,318,000 | 10,153,000 | 4,350,000 | 3,886,500 |
Operating Expenses | -23.8% | 49,127,000 | 64,454,000 | 65,893,000 | 65,530,000 | 38,841,000 | 50,176,000 | 49,182,000 | 55,623,000 | 43,439,000 | 56,258,000 | 55,721,000 | 59,793,000 | 33,320,000 | 23,271,000 | 12,364,000 | 12,108,000 | 13,785,000 | 10,934,000 | 10,725,000 | 10,858,000 | - |
S&GA Expenses | -6.5% | 12,507,000 | 13,377,000 | 13,225,000 | 13,762,000 | 11,860,000 | 12,488,000 | 10,993,000 | 10,730,000 | 10,806,000 | 10,860,000 | 10,042,000 | 9,743,000 | 9,034,000 | 5,572,000 | 4,420,000 | 4,191,000 | 1,791,000 | 3,881,000 | 3,456,000 | 3,534,000 | - |
R&D Expenses | -28.3% | 36,620,000 | 51,077,000 | 52,668,000 | 51,768,000 | 26,981,000 | 37,688,000 | 38,189,000 | 44,893,000 | 32,633,000 | 45,398,000 | 45,679,000 | 50,050,000 | 24,286,000 | 17,699,000 | 7,944,000 | 7,917,000 | 11,994,000 | 7,053,000 | 7,269,000 | 7,324,000 | - |
EBITDA Margin | -137.8% | -0.14 | 0.36 | 0.33 | 0.42 | 0.06 | -3.91 | -4.97 | -13.05 | -16.33 | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | 25,000 | - | - | 2,102,000 | 228,000 | 230,000 | 186,000 | 169,000 | 170,000 | 173,000 | 172,000 | 169,000 | 578,000 | -7,000 | -48,000 | 228,000 | 183,000 | 168,000 | 173,000 | 167,000 | - |
Income Taxes | -73.5% | 237,000 | 893,000 | 600,000 | 103,000 | - | - | - | 100,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 25.3% | -11,445,000 | -15,329,000 | -51,973,000 | 50,857,000 | 118,642,000 | -35,266,000 | -21,563,000 | -51,169,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -148.5% | -0.17 | 0.34 | 0.31 | 0.40 | 0.05 | -3.95 | -5.02 | -13.16 | -16.48 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 27.8% | -11,707,000 | -16,222,000 | -52,550,000 | 50,754,000 | 117,347,000 | -35,266,000 | -21,563,000 | -51,169,000 | -38,663,000 | -54,084,000 | -54,581,000 | -56,346,000 | -31,104,000 | -21,004,000 | -10,263,000 | -9,777,000 | -10,989,000 | -7,433,000 | -685,000 | -6,884,000 | - |
Net Income Margin | -153.1% | -0.18 | 0.34 | 0.30 | 0.40 | 0.05 | -2.85 | -4.08 | -12.83 | -16.48 | -22.28 | -18.74 | -13.16 | -7.56 | - | - | - | - | - | - | - | - |
Free Cashflow | 95.5% | -1,504,000 | -33,387,000 | 50,453,000 | -36,562,000 | 156,452,000 | -44,592,000 | -36,443,000 | -51,150,000 | -43,615,000 | -18,419,000 | -33,347,000 | -43,068,000 | -7,329,000 | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | -6.2% | 429 | 458 | 431 | 471 | 450 | 294 | 337 | 342 | 393 | 435 | 449 | 481 | 476 | 323 | 150 | 72.00 | 82.00 | 87.00 | 71.00 | 44.00 |
Current Assets | -1.7% | 387 | 393 | 385 | 425 | 403 | 247 | 292 | 327 | 379 | 421 | 438 | 470 | 468 | 314 | 142 | 64.00 | 74.00 | 79.00 | 63.00 | 42.00 |
Cash Equivalents | -6.4% | 292 | 312 | 323 | 328 | 392 | 238 | 283 | 320 | 370 | 414 | 434 | 467 | 463 | 307 | 136 | 59.00 | 71.00 | 74.00 | 56.00 | 37.00 |
Net PPE | -2.3% | 12.00 | 13.00 | 13.00 | 13.00 | 12.00 | 11.00 | 9.00 | 8.00 | 6.00 | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | -15.0% | 151 | 178 | 145 | 142 | 180 | 148 | 166 | 157 | 165 | 175 | 143 | 129 | 80.00 | 61.00 | 57.00 | 55.00 | 56.00 | 51.00 | 49.00 | 31.00 |
Current Liabilities | -6.5% | 82.00 | 88.00 | 90.00 | 90.00 | 127 | 76.00 | 93.00 | 107 | 100 | 118 | 71.00 | 53.00 | 50.00 | 28.00 | 23.00 | 22.00 | 21.00 | 22.00 | 16.00 | 13.00 |
Long Term Debt | -100.0% | - | 20.00 | - | - | - | 32.00 | 36.00 | 39.00 | 41.00 | 42.00 | 56.00 | 58.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | 10.00 | 10.00 | 10.00 |
LT Debt, Current | - | - | - | - | - | 61.00 | 28.00 | 27.00 | 24.00 | 22.00 | - | - | - | 1.00 | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 20.00 | - | - | - | 32.00 | 36.00 | 39.00 | 41.00 | 42.00 | 56.00 | 58.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | 10.00 | 10.00 | 10.00 |
Shareholder's Equity | -0.6% | 279 | 280 | 285 | 329 | 270 | 146 | 171 | 185 | 228 | 259 | 306 | 353 | 397 | 262 | 93.00 | 17.00 | 26.00 | 36.00 | 22.00 | 14.00 |
Retained Earnings | -3.3% | -367 | -356 | -339 | -287 | -338 | -455 | -420 | -398 | -347 | -308 | -254 | -200 | -143 | -112 | -91.71 | -81.44 | -71.70 | -60.68 | -53.25 | -44.87 |
Additional Paid-In Capital | 1.6% | 646 | 636 | 625 | 617 | 608 | 601 | 591 | 583 | 576 | 568 | 560 | 553 | 540 | 374 | 185 | 98.00 | 97.00 | 97.00 | 75.00 | 58.00 |
Shares Outstanding | 0.4% | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 692 | - | - | - | 376 | - | - | - | 700 | - | - | - | 701 | - | - | - | 76.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 98.1% | -629 | -32,406 | 50,807 | -35,871 | 160,259 | -42,406 | -36,821 | -49,039 | -42,497 | -16,653 | -32,943 | -42,950 | -6,632 | -15,877 | -8,494 | -11,858 | -7,538 | -2,836 | 9,340 | -5,411 | - |
Share Based Compensation | -4.9% | 8,815 | 9,269 | 8,383 | 8,182 | 6,530 | 9,436 | 7,274 | 7,371 | 7,518 | 6,870 | 7,540 | 6,987 | 2,826 | 1,988 | 1,101 | 849 | 797 | 383 | 403 | 399 | - |
Cashflow From Investing | 10.8% | -875 | -981 | -354 | -691 | -3,807 | -2,186 | 378 | -2,111 | -1,118 | -1,766 | -404 | -118 | -697 | -434 | -469 | -142 | -315 | -159 | -266 | -78.00 | - |
Cashflow From Financing | -185.4% | -18,657 | 21,840 | 94.00 | -27,364 | -2,232 | -1,220 | 257 | 336 | 230 | 692 | 82.00 | 47,012 | 163,201 | 187,223 | 85,603 | 118 | 5,034 | 21,327 | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
Total revenue | $ 166,799 | $ 205,999 | $ 12,359 |
Operating expenses: | |||
Research and development, net | 192,133 | 147,751 | 173,760 |
General and administrative | 52,871 | 46,071 | 41,451 |
Total operating expenses | 245,004 | 193,822 | 215,211 |
(Loss) income from operations | (78,205) | 12,177 | (202,852) |
(Loss) gain from equity-method investment | (515) | 515 | |
(Loss) gain from foreign currency | (229) | (598) | 584 |
Finance income (expense), net | 16,591 | (420) | (1,921) |
Gain on debt extinguishment | 33,953 | ||
Net (loss) income before income taxes | (27,890) | 10,644 | (203,674) |
Provision for income taxes | 1,835 | 1,295 | |
Net (loss) income | $ (29,725) | $ 9,349 | $ (203,674) |
(Loss) earnings per share: | |||
Basic | $ (1.12) | $ 0.35 | $ (7.74) |
Diluted | $ (1.12) | $ 0.35 | $ (7.74) |
Weighted-average shares used in calculation of (loss) earnings per share: | |||
Basic | 26,628 | 26,445 | 26,317 |
Diluted | 26,628 | 27,093 | 26,317 |
Comprehensive (loss) income: | |||
Net (loss) income | $ (29,725) | $ 9,349 | $ (203,674) |
Comprehensive (loss) income | (29,725) | 9,349 | (203,674) |
Collaboration Revenue [Member] | |||
Revenue: | |||
Total revenue | 157,748 | 205,755 | $ 12,359 |
Grant Revenue [Member] | |||
Revenue: | |||
Total revenue | $ 9,051 | $ 244 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 292,005 | $ 391,883 |
Restricted cash | 55,000 | |
Accounts receivable | 32,064 | 2,764 |
Prepaid expenses and other current assets | 7,521 | 8,686 |
Total current assets | 386,590 | 403,333 |
Property and equipment, net | 12,427 | 12,415 |
Operating lease right-of-use asset, net | 28,500 | 32,545 |
Non-current restricted cash | 1,885 | 2,094 |
Total assets | 429,402 | 450,387 |
Current liabilities: | ||
Accounts payable | 5,279 | 7,449 |
Accrued liabilities | 31,881 | 30,232 |
Current portion of long-term debt | 60,655 | |
Deferred revenue | 44,829 | 28,648 |
Total current liabilities | 81,989 | 126,984 |
Deferred revenue, net of current portion | 42,496 | 20,071 |
Operating lease liability, net of current portion | 25,907 | 30,216 |
Other non-current liabilities | 497 | 2,804 |
Total liabilities | 150,889 | 180,075 |
Stockholders’ equity: | ||
Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,828 at December 31, 2023 and 26,555 at December 31, 2022 | 27 | 27 |
Additional paid-in capital | 646,352 | 608,426 |
Accumulated deficit | (367,866) | (338,141) |
Total stockholders’ equity | 278,513 | 270,312 |
Total liabilities and stockholders’ equity | $ 429,402 | $ 450,387 |